UNASSIGNED: A total of 150 adult recipients who measured Mb within 3 days after liver transplantation between June 2019 and June 2021 were evaluated. Then, all patients were divided into two groups: the EAD group and the non-EAD group. Univariate and multivariate logistic regression analyses were performed, and receiver operating characteristic curves (ROCs) were constructed.
UNASSIGNED: The incidence of EAD was 53 out of 150 patients (35.3%) in our study. Based on the multivariate logistic analysis, the risk of EAD increased with elevated postoperative Mb (OR = 1.001, 95% CI 1.000-1.001, P = 0.002). The Mb AUC was 0.657, and it was 0.695 when combined with PCT. When the subgroup analysis was conducted, the AUC of serum Mb prediction was better in patients whose preoperative model for end-stage liver disease score ≤ 15 or operative time ≥ 10 h (AUC = 0.751, 0.758, respectively, or 0.760, 0.800 when combined with PCT).
UNASSIGNED: Elevated Mb significantly increased the risk of postoperative EAD, suggesting that postoperative Mb may be a novel predictor of EAD after liver transplantation.The study was registered in the Chinese Clinical Trial Registry (Registration number: ChiCTR2100044257, URL: http://www.chictr.org.cn).
UNASSIGNED:评估了在2019年6月至2021年6月之间肝移植后3天内测量Mb的150名成人接受者。然后,将所有患者分为两组:EAD组和非EAD组。进行了单变量和多变量逻辑回归分析,构建了受试者工作特征曲线(ROCs)。
UNASSIGNED:在我们的研究中,EAD的发病率为150例患者中的53例(35.3%)。基于多变量逻辑分析,EAD的风险随术后Mb升高而增加(OR=1.001,95%CI1.000~1.001,P=0.002)。MbAUC为0.657,与PCT联合为0.695。进行亚组分析时,术前模型终末期肝病评分≤15分或手术时间≥10h的患者血清Mb预测的AUC较好(AUC分别为0.751、0.758,或与PCT结合使用时的0.760、0.800)。
UNASSIGNED:Mb升高显著增加术后EAD的风险,提示术后Mb可能是肝移植术后EAD的新预测因子。该研究已在中国临床试验注册中心注册(注册号:ChiCTR2100044257,URL:http://www。chictr.org.cn)。